

19. [The use of claim] The medicament of claim 18, wherein the condition associated with immobilised IgG is an autoimmune disorder.

20. [The use of claim 16] The medicament of claim 19, wherein the autoimmune disorder is selected from rheumatoid arthritis, juvenile arthritis, Crohn's disease, type I insulin dependent diabetes, type II diabetes, sarcoidosis, erythema nodosum leprosum and tuberculosis.

21. [The use of claim 20] The medicament of claim 18, wherein the condition [antibody is for use for the diagnosis or treatment of] is erosive joint disease and the immobilised IgG is anti-type II collagen IgG.

22. [Use of a derivatised antibody of claim 7] A method for the in vivo diagnosis of a condition associated with immobilised IgG, [wherein the use comprises] the method comprising:

a. exposing a Patient to [said] the derivatised antibody of claim 7, which derivatised antibody has been labeled; and,

b. [using the] detecting the label, thereby [to detect] detecting the presence of the immobilised IgG.

A pharmaceutical composition comprising a derivatised antibody made by the method of claim 1, [in combination with] and a carrier.

REMARKS

The amendments to the claims merely conform the claims to U.S. practice and introduce no new matter. The claims are fully supported by the specification and claims as filed.

Thomas William Rademacher, et al.

Application No.: 09/622,253


Page 5

CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 510-337-7871.

LAW OFFICES OF
JONATHAN ALAN QUINE
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Jonathan Alan Quine".

Jonathan Alan Quine, J.D., Ph.D.
Reg. No. 41.261